Vitamin C Inhibits Lipopolysaccharide-Induced Hyperinflammatory State of Chronic Myeloid Leukemia Cells through Purinergic Signaling and Autophagy

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Autores
PIRES, Daniela A.
BRANDAO-RANGEL, Maysa A. R.
SILVA-REIS, Anamei
OLIMPIO, Fabiana R. S.
AIMBIRE, Flavio
OLIVEIRA, Carlos R.
MATEUS-SILVA, Jose R.
ZAMARIOLI, Lucas S.
BACHI, Andre L. L.
BELLA, Yanesko F.
Citação
NUTRIENTS, v.16, n.3, article ID 383, 14p, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the overproduction of white blood cells, leading to symptoms such as fatigue, infections, and other complications. CML patients must take measures to prevent infections to mitigate the exacerbation of cancer cell proliferation and comorbidities. Methods: This study investigated whether vitamin C can suppress the hyperinflammatory activation of K-562 cells induced by lipopolysaccharide (LPS) and whether purinergic signaling (ATP and P2X7 receptor) and autophagy play a role in it. Two different doses of vitamin C (5 mu g/mL and 10 mu g/mL) were employed, along with the lysosome inhibitor chloroquine (CQ; 100 mu M), administered 2 h prior to LPS stimulation (10 ng/mL) for a duration of 22 h in K-562 cells (3 x 10(5) cells/mL/well). Results: Both doses of vitamin C reduced the release of interleukin-6 (IL-6) (5 mu g/mL, p < 0.01 and 10 <mu>g/mL, p < 0.01) and tumor necrosis factor (TNF) (5 <mu>g/mL, p < 0.01 and 10 <mu>g/mL, p < 0.01) induced by LPS. Furthermore, in LPS + CQ-stimulated cells, vitamin C at a concentration of 10 <mu>g/mL inhibited the expression of LC3-II (p < 0.05). Conversely, both doses of vitamin C led to the release of the anti-inflammatory cytokine interleukin-10 (IL-10) (5 <mu>g/mL, p < 0.01 and 10 <mu>g/mL, p < 0.01), while only the 10 <mu>g/mL dose of vitamin C induced the release of Klotho (10 mu g/mL, p < 0.01). In addition, both doses of vitamin C reduced the accumulation of ATP (5 <mu>g/mL, p < 0.01 and 10 <mu>g/mL, p < 0.01) and decreased the expression of the P2X7 receptor at the mRNA level. Conclusions: Vitamin C inhibits the hyperinflammatory state induced by LPS in K-562 cells, primarily by inhibiting the ATP accumulation, P2X7 receptor expression, and autophagy signaling.
Palavras-chave
ascorbic acid, vitamin C, purinergic signaling, leukemia, autophagy, inflammation
URI
https://observatorio.fm.usp.br/handle/OPI/59255
Referências
  1. Agathocleous M, 2017, NATURE, V549, P476, DOI 10.1038/nature23876
  2. Alberca-Custódio RW, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00237
  3. Aldapt MB, 2023, ONCOLOGY-BASEL, DOI 10.1159/000534266
  4. Almeida-Oliveira A R, 2019, Exerc Immunol Rev, V25, P50
  5. ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994
  6. Aneja RK, 2011, MINERVA ANESTESIOL, V77, P986
  7. Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628
  8. Barbosa CMV, 2006, EUR J PHARMACOL, V542, P37, DOI 10.1016/j.ejphar.2006.06.004
  9. Bella YF, 2023, BIOMED PHARMACOTHER, V159, DOI 10.1016/j.biopha.2023.114263
  10. Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660
  11. Bestach Y, 2019, LEUKEMIA RES, V86, DOI 10.1016/j.leukres.2019.106221
  12. Cimmino L, 2017, CELL, V170, P1079, DOI 10.1016/j.cell.2017.07.032
  13. Cojbasic I, 2023, MEDICINA-LITHUANIA, V59, DOI 10.3390/medicina59091564
  14. Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771
  15. Crowley LC, 2011, AM J HEMATOL, V86, P38, DOI 10.1002/ajh.21914
  16. Donadieu J, 2005, HAEMATOLOGICA, V90, P45
  17. Drill M, 2021, PURINERG SIGNAL, V17, P215, DOI 10.1007/s11302-021-09776-9
  18. Drullion C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.111
  19. Ferrari D, 2000, FEBS LETT, V486, P217, DOI 10.1016/S0014-5793(00)02306-1
  20. Fitch BA, 2022, BLOOD ADV, V6, P854, DOI 10.1182/bloodadvances.2021005522
  21. Foster MN, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7070092
  22. Garcia M, 2019, EUR J IMMUNOL, V49, P928, DOI 10.1002/eji.201847657
  23. Gillberg L, 2018, SEMIN CANCER BIOL, V51, P59, DOI 10.1016/j.semcancer.2017.11.001
  24. Silva LMG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152890
  25. Holbrook Jonathan, 2019, F1000Res, V8, DOI 10.12688/f1000research.17023.1
  26. Huang XL, 2012, CANCER-AM CANCER SOC, V118, P3123, DOI 10.1002/cncr.26679
  27. Idzko M, 2014, NATURE, V509, P310, DOI 10.1038/nature13085
  28. Iwase S, 2019, AM J EMERG MED, V37, P260, DOI 10.1016/j.ajem.2018.05.040
  29. Razaul Karim M, 2017, BIOCHIMIE, V142, P51, DOI 10.1016/j.biochi.2017.08.004
  30. Larrouyet-Sarto ML, 2020, PURINERG SIGNAL, V16, P561, DOI 10.1007/s11302-020-09746-7
  31. Li Meng-Qi, 2015, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V23, P583, DOI 10.7534/j.issn.1009-2137.2015.02.056
  32. Liu X, 2017, LEUKEMIA, V31, P2376, DOI 10.1038/leu.2017.108
  33. Liu YB, 2023, DIAB MET SYND CLIN R, V17, DOI 10.1016/j.dsx.2023.102854
  34. Mackenzie B, 2016, MED SCI SPORT EXER, V48, P1459, DOI 10.1249/MSS.0000000000000927
  35. Franco DM, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011811.pub2
  36. Pavlovsky C, 2023, J HEMATOL ONCOL, V16, DOI 10.1186/s13045-023-01440-6
  37. Portugal CC, 2021, FREE RADICAL BIO MED, V163, P43, DOI 10.1016/j.freeradbiomed.2020.11.039
  38. Prud'homme GJ, 2022, FRONT AGING-LAUSANNE, V3, DOI 10.3389/fragi.2022.931331
  39. Rinaldi I, 2023, J BLOOD MED, V14, P261, DOI [10.2147/JBM.S382090, 10.2147/JBM.S382090Journalof]
  40. Rothe K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030461
  41. Sachdeva A, 2020, CANCERS, V12, DOI 10.3390/cancers12061665
  42. Sáez PJ, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah7107
  43. Sanchez-Correa B, 2013, CYTOKINE, V61, P885, DOI 10.1016/j.cyto.2012.12.023
  44. Schmid S, 2015, LUNG CANCER, V90, P516, DOI 10.1016/j.lungcan.2015.10.005
  45. Sharifzadeh S., 2023, Cardiovasc. Hematol. Agents Med. Chem, V21, P67, DOI [10.2174/1871525720666220819123639, DOI 10.2174/1871525720666220819123639]
  46. Shen N, 2019, ONCOTARGETS THER, V12, P2355, DOI 10.2147/OTT.S197535
  47. Shieh CH, 2014, GLIA, V62, P592, DOI 10.1002/glia.22628
  48. Singh P, 2021, MED ONCOL, V38, DOI 10.1007/s12032-021-01462-5
  49. Sun LR, 2022, DISCOV MED, V33, P93
  50. Tarumoto T, 2004, EXP HEMATOL, V32, P375, DOI 10.1016/j.exphem.2004.01.007
  51. Thompson DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030659
  52. Wang L, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1152-z
  53. Wang XS, 2014, CLIN CANCER RES, V20, P1366, DOI 10.1158/1078-0432.CCR-13-2442
  54. Willig JB, 2020, PURINERG SIGNAL, V16, P29, DOI 10.1007/s11302-019-09686-x
  55. Yan YL, 2017, MOL MED REP, V15, P1777, DOI 10.3892/mmr.2017.6172
  56. Yao X, 2014, PHARMACOL THERAPEUT, V141, P125, DOI 10.1016/j.pharmthera.2013.09.004
  57. Yu Y, 2012, LEUKEMIA, V26, P1752, DOI 10.1038/leu.2012.65
  58. Zhang LH, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.860526
  59. Zou D, 2018, BMC NEPHROL, V19, DOI 10.1186/s12882-018-1094-z

Coleções
Artigos e Materiais de Revistas Científicas - LIM/26